Prosecution Insights
Last updated: April 19, 2026
Application No. 17/920,169

METHOD OF TREATING SHIP1-MEDIATED DISEASES USING PELOROL DERIVATIVES

Final Rejection §102§112
Filed
Oct 20, 2022
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zebrapeutics Inc.
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
1y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
1317 granted / 1549 resolved
+25.0% vs TC avg
Minimal -5% lift
Without
With
+-4.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
47 currently pending
Career history
1596
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction The examiner notes for clarity of the record that inventor has added new claims 29-46. The subject matter of these new claims is encompassed by the original election/restriction requirement (an election of species across the entire claim set). Claim Objections Withdrawn The objections to claims 17 and 21, outlined in the previous Office Action, have been overcome by inventor’s amendment. The amendment cancels the claims. 112 Rejections Withdrawn The rejection of claim 12 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment clarifies the claim as appropriate. The rejection of claims 14-18, 21, 22, 27 and 28 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action (indefinite from indefinite), has been overcome by inventor’s amendment. The amendment cancels the claims. Claim Rejections - 35 USC § 112, NEW The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 36 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for compounds I-40, I-41, I, 42, I-46, I-50, I-51 and I-52. Claim 12, the claim from which claim 36 immediately depends, explicitly teaches that when R2 and R3, R3 and R4, or R4 and R5 are taken together to form a substituted or unsubstituted 5- or 6-membered heterocycle, then R4 and R5, R2 and R5, or R2 and R3, respectively, are independently H or C1-3 alkyl. That is, there is no antecedent basis for the moieties -OMe or -OH in the R5 position in compounds I-40, I-41, I, 42, I-46, I-50, I-51 and I-52. 102 Rejections Withdrawn The rejection of claims 1, 3-7, 11, 12, 14, 15, 17, 21, 22, 27 and 28 under 35 USC 102(a)(1), outlined in the previous Office Action, has been overcome by inventor’s amendment. With respect to claim 1, the amendment narrows the scope of the claimed subject matter such that it no longer reads on the cited art. With respect to claim 12, inventor’s amendment and arguments have been carefully considered and are persuasive. With respect to claims 3-7, 11, 14, 15, 17, 21, 22, 27 and 28, the amendment cancels the claims. Markush Search Inventor having overcome the outstanding art rejection, the search was expanded as called for under Markush examination practice, a compound-by-compound search. This resulted in all species being searched, with respect to Formula I of independent compound claim 1, and deemed free of the art. The search was expanded yet again, now with respect to Formula I of independent method claim 12, to include a single additional species. That species is defined when, using Formula 1 of claim 12: R1=OH; R2=R4=H; and R3=R5=OC1-3 alkyl (-OCH3). All claimed but as yet unexamined subject matter which does not read on the above species is hereby withdrawn from consideration, for purposes of this Office Action, as being drawn to non-elected subject matter. This subject matter will be rejoined as appropriate as the Markush examination progresses. Claim Rejections - 35 USC § 102, NEW In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 12, 30, 31, 38, 39, 45 and 46, in so far as they read on the above defined species, are rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by US 9,000,050 B2, cited in the IDS. The reference teaches the treatment of inter alia inflammatory bowel disease, where the inflammatory bowel disease is Crohn’s Disease and ulcerative colitis, via the modulation of SHIP1 by administering a pharmaceutical composition of the above compound (abstract; column 12, line 35 (diagramed compound); column 21, lines 32, 34, 49 and 54). (The examiner notes for clarity of the record that the cited reference teaches other compounds which are encompassed by instant formula I of claim 12 as well.) Allowable Subject Matter Claim 1 is allowed. Furthermore, the elected species now having been deemed free of the prior art vide supra, any claim, or portion of a claim, drawn exclusively to this species also constitutes allowable subject matter. That being the case, claims 29, 32, 37 and 40-44 are objected to because they encompass both allowable subject matter (the elected species) as well as subject matter which has not yet been completely searched. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 1/18/2026
Read full office action

Prosecution Timeline

Oct 20, 2022
Application Filed
Aug 30, 2025
Non-Final Rejection — §102, §112
Dec 03, 2025
Response Filed
Jan 18, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594226
COMPOSITION FOR AMELIORATING SKIN CONDITION
2y 5m to grant Granted Apr 07, 2026
Patent 12594257
MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS
2y 5m to grant Granted Apr 07, 2026
Patent 12594242
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595280
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
2y 5m to grant Granted Apr 07, 2026
Patent 12576107
METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
80%
With Interview (-4.8%)
1y 11m
Median Time to Grant
Moderate
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month